VCAM-1/α4β1 Signaling Inhibition for Osteosarcoma Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary metastasis of osteosarcoma (OS) are ineffective due to the complex genetic alterations in OS cells, which make molecular targeted therapy challenging, and there is a high propensity for lung metastasis, resulting in dismal outcomes for metastatic disease.
Innovation Solution
Targeting the VCAM-1/α4β1 signaling pathway between osteosarcoma cells and lung macrophages by down-regulating VCAM-1 expression, depleting pulmonary macrophages, or blocking VCAM-1/α4β1 signaling using therapeutic agents such as macrophage depletion compounds, VCAM-1/α4β1 integrin inhibitors, and anti-VCAM peptides to inhibit tumor growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for pulmonary metastasis of osteosarcoma, then treatment is provided, but the treatment is ineffective due to complex genetic alterations and high propensity for lung metastasis
Solution Approach 1:
The patent extracts and targets the specific VCAM-1/α4β1 signaling pathway from the complex genetic background of osteosarcoma. By identifying and isolating this particular interaction between osteosarcoma cells and lung macrophages, the treatment focuses on a discrete molecular mechanism rather than attempting to address all genetic alterations simultaneously, thereby achieving effective targeting despite overall genetic complexity
Solution Approach 2:
The patent introduces therapeutic agents as intermediaries that block the VCAM-1/α4β1 signaling pathway. These agents act as mediators between the osteosarcoma cells and lung macrophages, interfering with the metastatic signaling without requiring direct modification of the complex genetic machinery of the tumor cells themselves
2Reliability
If VCAM-1/α4β1 signaling is targeted to reduce metastasis, then pulmonary metastasis and tumor burden are reduced, but the complexity of delivering therapeutic agents to the lung increases
Solution Approach 1:
The patent employs therapeutic agents that can be administered systemically and then selectively accumulate at the site of action in the lung. The agents exploit the natural biodistribution and pharmacokinetics to reach the lung macrophages and osteosarcoma cells without requiring complex targeted delivery systems, thereby achieving effective metastasis inhibition with relatively simple delivery methods
Data Source
AI summary
A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/α4β1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing α4β1.